Parkinson’s Disease: Low-Dose Haloperidol Increases Dopamine Receptor Sensitivity and Clinical Response

Abstract EN

Background.

It is known that ultra-low doses of haloperidol can cause dopamine supersensitivity of dopamine D2 receptors and related behaviour in animals.

Objective.

The objective was to determine whether a daily ultra-low dose of 40 micrograms of haloperidol could enhance the clinical action of levodopa in Parkinson’s disease patients.

Method.

While continuing their daily treatment with levodopa, 16 patients with Parkinson’s disease were followed weekly for six weeks.

They received an add-on daily dose of 40 micrograms of haloperidol for the first two weeks only.

The SPES/SCOPA scale (short scale for assessment of motor impairments and disabilities in Parkinson’s disease) was administered before treatment and weekly throughout the trial.

Results.

The results showed a mean decrease in SPES/SCOPA scores after one week of the add-on treatment.

Conclusion.

SCOPA scores decreased after the addition of low-dose haloperidol to the standard daily levodopa dose.

This finding is consistent with an increase in sensitivity of dopamine D2 receptors induced by haloperidol.

Such treatment for Parkinson’s disease may possibly permit the levodopa dose to be reduced and, thus, delay the onset of levodopa side effects.